Skip to content

Mounjaro · Zepbound · weekly shot

Tirzepatide Dosage Chart: Mounjaro and Zepbound Doses

Tirzepatide is the medicine in both Mounjaro and Zepbound, with the same six strengths and the same four-week steps. The chart shows every dose and what each label says it's for; below it, what each step means, what to do when a dose is hard to tolerate or missed, and the questions the labels leave open.

Updated · From the Mounjaro and Zepbound prescribing information (revised 8/2026)

Tirzepatide dose steps in the Mounjaro and Zepbound labels (US)

Weekly doseEarliest startMounjaroZepbound
2.5 mgWeek 1Starting dose; also ongoing for blood sugarStarting dose only
5 mgWeek 5Step upMaintenance (weight)
7.5 mgWeek 9Step upStep up
10 mgWeek 13Step up; maximum in childrenMaintenance (weight or sleep apnea)
12.5 mgWeek 17Step upStep up
15 mgWeek 21Maximum in adultsMaximum; maintenance (weight or sleep apnea)

The weeks are the earliest each dose can start, at four weeks per step; they're not a timetable to follow. Your prescriber decides which medicine, which dose and when to step up.

Source: Mounjaro and Zepbound prescribing information (revised 8/2026)

Turn these steps into dates: the GLP-1 dose calendar

Quick answer

Tirzepatide starts at 2.5 mg once a week and can rise by 2.5 mg after at least four weeks on each dose, up to 15 mg. Mounjaro (type 2 diabetes) and Zepbound (weight management, sleep apnea) use these same steps. Zepbound's maintenance doses are 5, 10 or 15 mg; 2.5 mg is only a starting dose. Nobody has to reach 15 mg.

Log every tirzepatide step in Mingo

Save each shot with its dose and site, get reminded on shot day, and see each dose change marked on your weight chart, next to your side effects, meals and water.

Rated 4.7 out of 5 on the App Store · 1,579 ratings

See how Mingo tracks it: Tirzepatide Tracker

What each step is for

The chart has six rows, but they don’t all mean the same thing. Some are places to stay; others are stops on the way up (Zepbound and Mounjaro prescribing information):

  • 2.5 mg: where everyone starts, for at least four weeks, so the body can get used to the medicine. For Zepbound it’s never a dose to stay on. For Mounjaro, since August 2026, it can also be an ongoing dose for blood-sugar control.
  • 5 mg: the first possible maintenance dose for weight on Zepbound.
  • 7.5 mg: a step on the way to 10 mg.
  • 10 mg: a maintenance dose for weight or sleep apnea on Zepbound, and the highest Mounjaro dose for children 10 and older.
  • 12.5 mg: a step on the way to 15 mg.
  • 15 mg: the maximum. A maintenance dose for weight or sleep apnea on Zepbound.

You don’t have to reach 15 mg. The Zepbound label asks prescribers to pick the maintenance dose based on how you respond and what you tolerate, and 5 and 10 mg are maintenance doses in their own right.

When a dose is hard to tolerate

Digestive side effects are the main reason the steps are slow, and they tend to rise with the dose. In the Zepbound weight-reduction trials, nausea affected 25%, 29% and 28% of people on 5, 10 and 15 mg, against 8% on placebo (Zepbound prescribing information). The days after a step-up are usually the hardest.

The labels give your prescriber two levers. Each increase comes after at least four weeks, so staying longer on a dose before moving up is within the label. And if a maintenance dose isn’t tolerated, the Zepbound label says a lower maintenance dose can be considered.

In practice, a multidisciplinary expert consensus on digestive side effects of this class of medicines describes the usual order of steps (Gorgojo-Martínez et al., J Clin Med 2022):

  1. Change how you eat first: smaller meals, stopping as soon as you feel full, less fatty, fried or spicy food, and fluids sipped between meals rather than with them.
  2. Hold the dose: stay on the current step for longer instead of moving up on schedule.
  3. Step back: if symptoms started after an increase, return to the previous dose for a while, then go up more slowly.
  4. Settle lower: a maintenance dose below the maximum is a fine place to stay.

The SURMOUNT-1 trial worked the same way. Participants with digestive symptoms got eating advice first and could take anti-nausea or anti-diarrhea medicine. If that wasn’t enough, they could skip one dose, and then move down once to the next maintenance dose (15 to 10 mg, or 10 to 5 mg). Those who still couldn’t tolerate it stopped (SURMOUNT-1 protocol). Each of these steps is your prescriber’s call; the list is there so you know what to ask about.

Call your prescriber promptly if you have severe stomach pain that doesn’t go away, sometimes reaching through to the back (the label lists it as a possible sign of pancreatitis); vomiting or diarrhea that keeps you from holding down fluids, since dehydration can harm the kidneys; or pain in the upper right belly, fever or yellowing skin, which can point to the gallbladder (Zepbound prescribing information). Our tirzepatide side effects guide covers the rest.

What each maintenance dose did in the trial

In SURMOUNT-1, adults with obesity and without diabetes were assigned one maintenance dose and stayed on it (Jastreboff et al., NEJM 2022):

Maintenance dose Average weight lost after 72 weeks
5 mg 15.0%
10 mg 19.5%
15 mg 20.9%
Placebo 3.1%

These are averages across thousands of people, alongside diet and exercise advice. Individual results vary a lot, in both directions.

Missed doses, late doses and changing your day

Situation What the label says
4 days (96 hours) or less since the missed day Take it as soon as possible
More than 4 days Skip it; take the next dose on your usual day
Moving your shot day Allowed if the two doses are at least 3 days (72 hours) apart
Missed several weeks in a row No rule in the labels; ask your prescriber which dose to restart on before your next shot

The first three rows come from both labels. For longer breaks, the closest thing to an answer is what the SURMOUNT trials did, as Eli Lilly’s medical information team describes it: after one or two missed doses in a row, people restarted at the same dose if they’d tolerated it before; after three or more, they restarted at 5 mg, whatever dose they’d been on, and stepped up again from there (Lilly Medical, reviewed January 2026). That’s trial practice, not a dosing instruction, but it shows why going straight back to 15 mg after a month off is something to talk through first: side effects are dose-related, and the body has lost its tolerance.

Pens, KwikPens and vials

All four devices hold the same medicine, and every dose on the chart is in milligrams whichever you use.

Device Weekly doses inside Out of the refrigerator
Single-dose pen 1 Up to 30 °C (86 °F) for a total of 21 days
Single-dose vial 1 Up to 30 °C (86 °F) for a total of 21 days
KwikPen 4 Discard 30 days after first use or after 4 doses
Multi-dose vial 4 Discard 30 days after first use or after 4 doses

Before use, all of them are kept in the refrigerator (2–8 °C / 36–46 °F). Single-dose pens and vials come in all six strengths. Inject under the skin of the abdomen or thigh, or the back of the upper arm if someone else gives the shot, and rotate the site each week (Zepbound prescribing information).

One medicine, two labels

Mounjaro and Zepbound are both tirzepatide from Eli Lilly, in the same strengths and with the same four-week steps. Where they differ is what each dose is for: Zepbound names maintenance doses for weight and sleep apnea and treats 2.5 mg as a starting dose only; Mounjaro, for type 2 diabetes, allows 2.5 mg as an ongoing dose and caps children at 10 mg. Each brand has its own page: the Mounjaro dosage chart and the Zepbound dosage chart. Outside the US, Mounjaro is also authorised for weight management in the UK and EU, with the same steps.

Before surgery, during pregnancy, and with the pill

  • Surgery or sedation: tell the team doing any planned surgery or procedure that you take tirzepatide. The label warns about the risk of breathing in stomach contents under general anesthesia or deep sedation.
  • Pregnancy: the Zepbound label says to stop when a pregnancy is recognized. Talk to your prescriber if you’re planning one.
  • Birth control pills: tirzepatide can make them less effective. Both labels advise switching to a non-oral method, or adding a barrier method, for four weeks after starting and for four weeks after each dose increase. That’s one more reason to keep the dates of your steps.

Questions the labels leave open, and what we found

Some of the most searched questions about tirzepatide dosing have no answer in the prescribing information. Here’s what the manufacturer’s medical team and the trials say instead, and where the honest answer is “no one knows”:

  • Switching from semaglutide (Ozempic or Wegovy): there’s no official method and no dose equivalence. Lilly says plainly that it can’t recommend how to switch from another GLP-1 medicine to tirzepatide or give a conversion between them (Lilly Medical). In two switching trials in type 2 diabetes, there was no gap between the medicines: one started tirzepatide at 2.5 mg within three days of the next scheduled dose of the old one; the other started at 5 mg, three to ten days after the last weekly dose. Any “semaglutide to tirzepatide conversion chart” you find online isn’t based on either label.
  • Restarting after weeks off: see the table above. The labels are silent; the trials restarted at 5 mg after three or more missed doses.
  • Microdosing or splitting a dose: Lilly doesn’t recommend it. It hasn’t studied splitting a KwikPen or multi-dose vial into smaller doses, the instructions don’t cover giving less than the full dose, and splitting a single-dose pen or vial may raise the risk of contamination (Lilly Medical, reviewed August 2026). If the lowest maintenance dose is too much, that’s a conversation for your prescriber, not a pen to divide.
  • Syringe units for compounded tirzepatide: see the next section.

Compounded tirzepatide and syringe units

Many people searching for a tirzepatide dosage chart use tirzepatide from a compounding pharmacy, drawn from a vial with a syringe marked in units. How many units make a given number of milligrams depends on the concentration of that vial, and concentrations differ between pharmacies. A units chart from one pharmacy can be wrong, by a lot, for a vial from another. That’s why this chart lists milligrams only: the units for your dose come from your own pharmacy’s label and your prescriber.

The risk isn’t theoretical. With compounded semaglutide, sold the same way, the FDA received reports of people injecting five to 20 times the intended dose after mixing up milliliters, milligrams and units, some of whom were hospitalized (FDA, July 2024). If the numbers on your vial, syringe and instructions don’t line up, ask your pharmacist before you inject.

The FDA states that compounded drugs are not FDA-approved, meaning the agency doesn’t review them for safety, effectiveness or quality before they’re sold (FDA). The FDA declared the tirzepatide injection shortage, which had allowed wider compounding, resolved in December 2024 (FDA).

Keeping a record of each step

Six possible doses, a birth-control window after each increase, and a four-day missed-dose cutoff add up to a lot of dates. Mingo saves the dose with every shot and colors the weight chart by dose, so after a few months you can see which step brought the most change and which brought side effects. It also draws an estimated medication level from your logged doses and tirzepatide’s half-life of about five days, which helps make sense of how you feel across the week. Mingo accepts any dose in milligrams, including compounded tirzepatide, but it doesn’t convert syringe units; that math belongs to your pharmacist and prescriber.

Frequently asked questions

What is the starting dose of tirzepatide?

2.5 mg once a week, for at least four weeks, in both Mounjaro and Zepbound.

How much does the tirzepatide dose go up each time?

2.5 mg, after at least four weeks on the current dose: 2.5, 5, 7.5, 10, 12.5 and 15 mg.

Do I have to go up to 15 mg?

No. 15 mg is the maximum, not a target. The Zepbound label has three maintenance doses (5, 10 and 15 mg) and says to choose one based on how you respond and what you tolerate.

What if a tirzepatide dose makes me too sick?

Tell your prescriber. The usual steps are changing how you eat, staying longer on the current dose, going back to the previous one, or settling on a lower maintenance dose; the Zepbound label allows that last one. Severe stomach pain that won't go away needs a call right away.

How do I switch from semaglutide to tirzepatide?

Your prescriber decides. Lilly says there's no recommended switching method and no dose equivalence between the two. In switching trials, tirzepatide started without a gap, at 2.5 mg or 5 mg.

Can I split or microdose a tirzepatide pen?

Lilly doesn't recommend it: splitting hasn't been studied, the instructions only cover the full dose, and splitting single-dose products may raise the risk of contamination.

What is the maximum dose of tirzepatide?

15 mg once a week in adults. For Mounjaro in children 10 and older, the maximum is 10 mg.

Are Mounjaro and Zepbound doses the same?

The strengths and steps are the same. The difference is the approval: in the US, Mounjaro is for type 2 diabetes and Zepbound for weight management and obstructive sleep apnea.

How many units of compounded tirzepatide is my dose?

It depends on the concentration of your vial, which differs between pharmacies, so there's no general answer. Use the dosing instructions from your pharmacy and prescriber; this chart lists doses in milligrams only.

What if I miss a tirzepatide dose?

Take it within four days (96 hours) of the missed day. After that, skip it and take the next dose on your usual day. Never take two doses less than three days apart.

How many doses are in a tirzepatide KwikPen or multi-dose vial?

Four weekly doses. They're discarded 30 days after first use or after four doses, whichever comes first.

Sources

Medication facts on this page come from the official prescribing information and the studies listed here. Your prescriber sets your dose and schedule. Updated .

  1. Zepbound prescribing information, revised 8/2026 (DailyMed)
  2. Mounjaro prescribing information, revised 8/2026 (DailyMed)
  3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med 2022
  4. SURMOUNT-1 study protocol (I8F-MC-GPHK), sections on tolerability and missed doses (ClinicalTrials.gov)
  5. Gorgojo-Martínez JJ et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med 2022
  6. Lilly Medical: What should a patient do if they miss a dose of Zepbound? (reviewed January 29, 2026)
  7. Lilly Medical: Switching to Mounjaro from a GLP-1 receptor agonist (reviewed February 28, 2025)
  8. Lilly Medical: Can a dose of Zepbound be split into smaller doses? (reviewed August 25, 2026)
  9. FDA alerts health care providers, compounders and patients of dosing errors associated with compounded injectable semaglutide products (July 26, 2024)
  10. FDA: Concerns with unapproved GLP-1 drugs used for weight loss
  11. FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize

Dose charts for other GLP-1 medications